Syngene International Limited, a contract research and manufacturing company, delivers drug discovery and development services globally, operating in India, the United States, and other international markets. The company offers a range of services encompassing discovery chemistry, including medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry. Additionally, it provides discovery biology services covering recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals.
Syngene also specializes in exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, along with acute, sub-chronic, and chronic toxicity studies. The company extends its expertise to chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. It further engages in lead generation, preclinical development, API, and drug product development services, along with clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services.
Moreover, Syngene offers services for various drug modalities, including peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy. The company caters to diverse industries such as pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and others. Established in 1993, Syngene International Limited is headquartered in Bengaluru, India, and operates as a subsidiary of Biocon Limited. The company has established partnerships and collaborations with Bristol-Myers Squibb Co., Baxter Inc., and Amgen Inc.
Syngene also specializes in exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, along with acute, sub-chronic, and chronic toxicity studies. The company extends its expertise to chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. It further engages in lead generation, preclinical development, API, and drug product development services, along with clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services.
Moreover, Syngene offers services for various drug modalities, including peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy. The company caters to diverse industries such as pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and others. Established in 1993, Syngene International Limited is headquartered in Bengaluru, India, and operates as a subsidiary of Biocon Limited. The company has established partnerships and collaborations with Bristol-Myers Squibb Co., Baxter Inc., and Amgen Inc.
